Recent

% | $
Quotes you view appear here for quick access.

Royal Gold, Inc. Message Board

Posts containing “”: 2233749 results
SortMost Relevant  |  Newest  |  Oldest Expand all messages
  • You mean my / our little friend Beaufort the Kraken ! BOOOOOOOOOOOOOOOM!

    Sentiment: Strong Buy

  • Reply to

    Contact Investor Relations

    by cpeel9111 May 1, 2015 12:42 AM

    I agree with you 100%

  • Fake ariad_lnvestor 冒充 (impersonates) the real ariad_investor. 此冒名者是猪狗不如的狗杂种(3/4狗1/4猪). 该孽畜冒充 all the true longs filthily. 这畜生的姥姥 fake grandma_of_jbraik 比他更肮脏. The impersonator and basher has confessed he is iAndy, who succesfully talked some people into selling ARIA at $2's early Nov., 2013. His most famous bashing ID is pork_sandwiches

    Sentiment: Strong Buy

  • (Reuters) - Detroit's automakers, on track for their best sales year since 2006, may want to brace themselves for rockier times ahead.

    Auto executives say the industry is as healthy as it's been since being restructured in 2009. But judging by the recent stock performance of General Motors Co, Ford Motor Co and Fiat Chrysler Automotive, investors have a less robust view.

    Over the past year, GM and Ford share prices have lagged the overall market, in spite of moves by those two companies to give more cash back to shareholders. Fiat Chrysler prices plunged last week as Chief Executive Sergio Marchionne made increasingly overt efforts to drum up interest in a merger with one of his rivals.

    "The party may be starting to wind down," said Charles Chesbrough, senior principal economist for IHS Automotive. "We're still looking at a good couple years of strong demand, but the days of big sales increases are behind us."

    Optimists include Kurt McNeil, head of GM's U.S. sales operations, who said Friday that the industry is on track to have its best sales year since 2006. U.S. sales of cars and light trucks are estimated to reach 17 million in 2015, compared with about 10 million in 2009.

    U.S. consumer confidence is up, house prices are recovering and gasoline costs less than $4 a gallon in most parts of the country, supporting sales of the big trucks and SUVs that drive profits for the Detroit Three, just as they did before the financial crisis crash in 2008-2009.

    But there are warning signals. Sales growth is slowing in the home market, demand for small cars and family sedans is falling, revenues have declined, profits outside North America and China are virtually nonexistent and share prices have flattened.

    All three Detroit automakers missed analysts' expectations for first-quarter earnings. After reporting healthy April U.S. car sales on Friday, stocks fell again at all three.

    U.S. sales growth this year has slowed to 6 percent from double digits in 2010-2012. As demand slows, and more companies add production capacity in North America, competition from Asian and European rivals using cheap currencies will intensify. GM's share of the North American market in the first quarter slipped to 16.4 percent in the first quarter from 16.5 percent a year earlier.

    "Over the next couple years, we expect to see the industry cycle down — not next year, but 2017," said John Hoffecker, managing director and global vice chairman of operations at AlixPartners. Detroit automakers have had "a good strong, long run," but "there will be a correction from where we are today."

    Before the next downturn, the U.S. carmakers "need to find long-term solutions to sustainable profitability and cost competitiveness," said Xavier Mosquet, global automotive practice leader for the Boston Consulting Group. "That may be their biggest challenge."

    Part of that solution may be to reduce their dependence on the U.S. market.

    The companies need to reduce excess production capacity overseas, especially in Europe and South America, said Matthew Stover, auto analyst with Susquehanna Financial Group. And as U.S. demand slows, they need to generate a higher return on their overseas investments.

    Ford and GM are losing money in Europe even after restructuring efforts that included plant shutdowns. GM has said it expects to return to profitability in Europe in 2016. In Latin America, GM and Ford are losing money as the Brazilian economy slows and economic turmoil wracks Venezuela, where Ford earlier this year took an $800 million pre-tax writedown. GM has signaled it could stop Venezuelan production in July. In China, GM's profit margins fell to 9.9 percent in the first quarter from 11.2 percent a year earlier.

    "GM and Ford earn terrific rates of return in North America, but they're getting killed in Europe and South America," Stover said.

  • The first two areas to see robots are landscaping and fast food.
    Imagine a fast food restaurant with self ordering, robots cooking and cleaning, and only one or two humans there to run the place.

  • on huge volume..............2.51 on Monday ..2.77 Friday.............nice

  • Reply to

    Sunday Conjecture

    by irishtrader52 May 3, 2015 10:14 AM

    Thanks Irish! As usual, a breathe of fresh air.

  • Reply to

    UR be careful ,,,,& AR

    by eddiebrown308 May 3, 2015 10:04 AM

    No not at all,,,,,but it is a pleasure seeing all you go to church on sunday people here bashing our president and our country

  • I can't wait to vote in new leadership. Goldberg and Ricky get a job working on the line, an honest job for a change!

  • HONOR, WHAT SAY YOU......?

    Sentiment: Strong Buy

  • This SCAM was born in 1979 on the Vancouver Exchange!

  • Analysts have average estimates of $600K for Q1 and $830K for Q2 -- $1.4M for first half.

    In Q4 call, company stated that it sees first quarter revenue approaching the $1.2M product revenue for all of 2014. That was further validated by CEO stating that the $2M backlog typically gets filled in 6 months.

    Absent outright misleading guidance, it appears that Q1 could be a substantial beat.

    Hoping for further customer traction and meaningful progress on bi-directional inverter technology. The later is and its potential to expand IPWR into traditional markets (including traction) is an embedded option that is not, in my opinion, reflected in this stock's price as yet.

    Energy storage is where solar was several years ago. It is greatly underappreciated and as SCTY or Tesla recently pointed out, customers are surprised to find out how economically compelling the returns are. With financing now being provided, many others than just Walmart will be making solar part of the PV package. I recently read a study suggesting 10% of PV install in a few years will include storage. I think that 10% number will prove much too conservative, but even the 10% presents a material market opportunity. And then there are microgrids. The payback for displacing diesel is roughly 2 years, explaining why large players are looking to jump into this market.

    This stock is not without risks, but this small company has a sizable potential runway in front of it.

  • Unfortunately, liquidity is all the system has left. Which is also why, in the current system, there will never be a capex recovery, and instead all dollars will ultimately go to purchase every last share of stock until the market spontaneously combusts in a thought experiment supernova in which companies with zero employees have an infinite market cap, thus breaching the monetarist event horizon, and crossing the Keynesian streams.

  • Reply to

    HELM2WAR = 100% BULLSCHIT

    by stephentalley Apr 19, 2015 4:16 PM

    Oh what the just for the Pumpers have something to post over

  • rante@att.net rante May 3, 2015 10:41 AM Flag

    True dat...Nobel price winner.
    My true concern is DSMB & FDA is too slow in coming up with decisions specially with small co. like NWBO. Very obvious that if the data that we have is from a WHALE pharma this will garner already a BREAKTHROUGH status.
    Regardless being timid & just ignoring strong data will not last.
    Germany EU UK will bring this to market very shortly.
    The stage is set.
    We all stay tune -ACCUMULATE
    It's all about systemic approach. CART cells is limited effectivity, DCVAX will be the leader in IMMUNO-ONCOLGY. We just need to be patient.
    FYI: Watchout double digits nearby. We are still very UNDERVALUED @ this level.
    With DCVAX-L about to conclude & DCVAX-DIRECT { targeting several cancer indications } We are a force that cannot be ignored , cannot be subdued by DSMB & FDA.
    DATA is impeccably very strong .

    Peace
    We are it.
    Double digits is coming
    DDRANTE @Twitter for other links for reading

  • 2837485968574839485984 4859605948394850999999

  • Reply to

    The truth about uplisting ...

    by gpls72 May 1, 2015 9:37 AM

    I agree with everything you wrote.
    Aside from the "patience" that you emphasize what is also required is the realism that FDA approval of Bril is not a certainty. The results the company showed from the Phase 2 study show a signal for hypertension even at the one time 0.8 mg/kg dose (17% had a systolic bp greater than 160). Less than 4% had systolic bp greater than 160 in the 0.6 mg/kg dose while 10% in the daptomycin arm of the study had systolic bp greater than 160.
    So the 0.6 mg/kg one time dose looks to be effective and so far, has not shown the hypertension side effect to a prohibitive degree. However, as I recall , there were only about 51 patients in each arm of the study so need a lot more patients to be studied at 0.6 mg/kg.
    Also, CTIX has to establish a minimum effective dose, especially with the specter of hypertension. So I'm guessing they have to analyze the MIC (minimum inhibitory concentrations) and pharmacokinetics and come up with a lower dose than 0.6 mg/kg to study.
    If I were the FDA, I'd suggest doing another similar Phase 2, maybe with 0.4 mg, 0.5 mg and 0.6 mg/kg one dose arms and would have an active comparator like Vancomycin every 12 hours for one week or Daptomycin weekly x 2.
    But from CTIX' statements they are expecting the FDA's guidance to allow them to start a e Phase 3 by 12/31/15. Is there an End of Phase 2 meeting with the FDA? Would be a big mistake not to have one.
    Hopefully the efficacy and safety seen with 0.6 mg/kg in the Phase 2 will also be seen in the larger Phase 3.
    I think it would also be a big mistake to have a 0.8 mg/kg arm in the next study because there was too much hypertension associated with that dose in the Phase 2.

  • It was at $1.457 per their April 10 PR.

  • http://www.medscape.com/viewarticle/843261?src=wnl_edit_specol&uac=207701DN

RGLD
50.20-0.22(-0.44%)10:00 AMEDT